Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism

Eur J Clin Pharmacol. 1996;50(1-2):7-18. doi: 10.1007/s002280050062.

Abstract

Rationale: Poor specificity of face-value endpoints and the poor sensitivity of gross clinical examination may have militated against demonstrating prophylaxis by selegiline.

Methods: Objective measures of the four cardinal signs were used as primary outcome criteria in a randomised, double-blind, placebo-controlled, parallel group study of selegiline monotherapy in 25 newly diagnosed elderly sufferers from idiopathic parkinsonism, stratified for sex and Hoehn and Yahr functional staging.

Results: There was a significant interaction between time and nature of treatment with respect to rigidity. The effect of time during active treatment was highly significant: rigidity decreased by 1.3% per week. The worsening of rigidity on placebo was not statistically significant. Neuronal rescue is a possible explanation for the long term, progressive improvement produced by selegiline. No significant treatment effect was seen on the other cardinal signs. However, there was a significant quadratic time trend for arousal on active treatment suggesting tolerance to this effect.

Conclusion: The difference in time course between the psychostimulant and physical effects suggests more than one mode of action.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Antiparkinson Agents / pharmacokinetics
  • Antiparkinson Agents / therapeutic use*
  • Arousal / physiology
  • Double-Blind Method
  • Female
  • Gait / drug effects
  • Gait / physiology
  • Humans
  • Hypokinesia / drug therapy
  • Hypokinesia / physiopathology
  • Male
  • Muscle Rigidity / drug therapy
  • Muscle Rigidity / physiopathology
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Parkinson Disease / psychology
  • Posture / physiology
  • Psychomotor Performance / drug effects
  • Research Design
  • Selegiline / pharmacokinetics
  • Selegiline / therapeutic use*
  • Treatment Outcome
  • Tremor / drug therapy
  • Tremor / physiopathology

Substances

  • Antiparkinson Agents
  • Selegiline